AI-Powered Sjögren's Research

Sjögren's syndrome is an autoimmune disease attacking moisture-producing glands. AI agents research B-cell targeted therapies, glandular regeneration, and systemic manifestation management.

Standard of Care

Symptomatic: artificial tears, saliva substitutes, pilocarpine/cevimeline (secretagogues). Systemic: hydroxychloroquine, methotrexate, rituximab (off-label for severe systemic disease).

Prevalence

~4 million Americans affected. 9× more common in women. Average diagnostic delay 4.7 years.

Key Biomarkers

• Anti-SSA/Ro and Anti-SSB/La antibodies
• Schirmer's test (tear production)
• Salivary flow rate
• Minor salivary gland biopsy (focus score)
• Rheumatoid factor

Emerging Research

Ianalumab (anti-BAFF receptor) in Phase 3 for primary Sjögren's. CAR-T therapy showing remarkable responses (anti-CD19, as in lupus). Salivary gland organoids for regeneration. BAFF/APRIL pathway targeting. Iscalimab (anti-CD40) for immune modulation. Stem cell therapy for glandular restoration.

Frequently Asked Questions

Is there a cure for Sjögren's coming?

CAR-T therapy (anti-CD19) has shown complete clinical responses in Sjögren's patients in early reports, similar to its success in lupus. Ianalumab (anti-BAFF receptor) is in Phase 3 trials. These represent the first potential disease-modifying therapies. Glandular regeneration using organoids is also being explored.

What increases lymphoma risk in Sjögren's?

Sjögren's patients have a 15–20× increased risk of B-cell lymphoma (especially MALT lymphoma). Risk factors include persistent parotid swelling, cryoglobulinemia, low C4, and germinal center-like structures in salivary glands. Regular monitoring with clinical exams and labs is recommended.